Lusatrombopag is a thrombopoietin receptor agonist primarily used for the treatment of thrombocytopenia in patients with specific liver dysfunction. The applicable population requires strict assessment of liver function status, with clear medication restrictions, and attention should be paid to potential interactions with multivalent cationic drugs.

1. Applicable population

(1) Chronic liver disease patients: suitable for adult patients with chronic liver disease and thrombocytopenia who plan to undergo invasive procedures.

(2) Liver function classification: Child Pugh A or B patients can use it safely, while Child Pugh C patients need to be evaluated carefully.

(3) Age restriction: Elderly patients (≥ 65 years old) do not need to adjust the dosage, but monitoring needs to be strengthened.

2. Restrictive conditions

(1) Pregnancy: Lack of sufficient human data, potential risks to the fetus should be communicated, and use is not recommended.

(2) Breastfeeding period: Animal experiments have shown that drugs can enter breast milk. Breastfeeding should be stopped during the treatment period and 28 days after discontinuation of medication.

(3) Children: Safety and efficacy have not been established yet, and pediatric use is not recommended.

(4) Liver function: Patients with severe liver dysfunction (Child Pugh C grade) may experience a 20% -30% decrease in blood drug concentration.

3. Drug interactions

(1) Multivalent cationic drugs, such as antacids and mineral supplements, have no significant clinical impact on drug exposure.

(2) Specific drugs: When used in combination with calcium carbonate, cyclosporine, etc., no significant changes in mutual exposure were observed.

(3) Metabolic pathway: Mainly metabolized through UGT1A1 and UGT1A3, attention should be paid to the effects of related enzyme inducers or inhibitors.